Afamelanotide alternatives.
8 compounds compared to Afamelanotide, ranked by published evidence tier and regulatory status, not by what's marketed hardest.
Afamelanotide is one of the very few alpha-MSH analogs to complete Phase 3 development and win approval, so alternatives searches here are rarely about evidence. They are about access and about a misunderstanding. Scenesse is a bioresorbable implant placed by a trained physician and approved to increase pain-free light exposure in adults with erythropoietic protoporphyria, a narrow orphan indication, so people outside that diagnosis cannot get it. Many arrive expecting a tanning drug and find a photoprotective treatment for a rare inherited condition instead. Melanotan-branded tanning products are the usual next search, and those are unapproved drugs in many jurisdictions rather than a legitimate substitute.
Afamelanotide is a synthetic 13-amino-acid analog of alpha-melanocyte-stimulating hormone (alpha-MSH), historically studied under the research name Melanotan I.
- 01PT-141B tierFDA-approvedbremelanotide · Vyleesi
Acts through the melanocortin receptor activation pathway, like Afamelanotide. FDA-approved.
- 02Melanotan IID tierResearch / preclinical
Acts through the melanocortin receptor activation pathway, like Afamelanotide. Research / preclinical.
- 03KPVF tierResearch / preclinical
Acts through the melanocortin receptor activation pathway, like Afamelanotide. Research / preclinical.
- 04
- 05ArgirelineD tierCosmetic / topicalacetyl hexapeptide-8
Same category: skin & cosmetic. Cosmetic / topical.
- 06MatrixylD tierCosmetic / topicalpalmitoyl pentapeptide
Same category: skin & cosmetic. Cosmetic / topical.
- 07SNAP-8D tierCosmetic / topicalacetyl octapeptide-3
Same category: skin & cosmetic. Cosmetic / topical.
- 08PTD-DBMF tierResearch / preclinical
Same category: skin & cosmetic. Research / preclinical.
An “alternative” here means a compound that shares Afamelanotide's mechanism pathway or sits in the same category, not a marketing substitute. Each is ordered by PepCue's evidence tier (a weighted 0–100 score across human data, safety, replication and regulatory clarity), then by whether it's actually approved. This is a research reference, not medical or purchasing advice: an alternative sitting higher on evidence does not mean it's right, safe, or legal for any given use. Reviewed June 1, 2026.
PepCue keeps every compound, dose and lab in one private, provider-ready timeline, whichever one you land on.